60 Degrees Pharmaceuticals Begins Enrolling For A Clinical Trial Of Tafenoquine For Babesiosis At Tufts Medical Center

Author: Benzinga Newsdesk | May 30, 2024 08:01am

60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in humans
The study will be the world's first clinical trial to evaluate tafenoquine in human babesiosis patients
Enrollment will begin after a site initiation visit in Boston on June 13, 2024
Agreements are being negotiated with two other prominent university hospitals to expand recruitment in the Northeast U.S. where the incidence of babesiosis has been increasing; babesiosis, a tick-borne and potentially life-threatening illness, is an orphan disease
Case studies in the medical literature suggest that tafenoquine may be a promising alternative for the treatment of some patients hospitalized with relapsing babesiosis

WASHINGTON, May 30, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))))) (the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has entered into an agreement with Tufts Medical Center in Boston to conduct the world's first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients.

Posted In: SXTP